Concepedia

Jeffrey Unger

JU

10

Publications

1.1K

Citations

10

H-Index

2003

Active since

Affiliations

Catalina Research Institute(Current)

Novo Nordisk (Denmark)

Jeffrey Unger is an author at Catalina Research Institute specializing in medicine, diabetes, and pharmacotherapy.

Top concepts

Publications per year

2003–2018

10

Publications

10

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Christopher Sorli, Shin‐ichi Harashima, George Tsoukas et al. · The Lancet Diabetes & Endocrinology · 2017 · 648 citations · Full text

, , +7

Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial

Vanita R. Aroda, Julio Rosenstock, Carol Wysham et al. · Diabetes Care · 2016 · 245 citations · Full text

Effect of Pain Intensity and Time to Administration on Responsiveness to Almotriptan: Results from AXERT <sup>®</sup> 12.5 mg Time Versus Intensity Migraine Study (AIMS)

Frederick G. Freitag, Gary Finlayson, Alan M. Rapoport et al. · Headache The Journal of Head and Face Pain · 2007 · 40 citations

Glucagon-like peptide-1 (GLP-1) receptor agonists: Differentiating the new medications

Jeffrey Unger, Christopher G. Parkin · Diabetes Therapy · 2011 · 36 citations · Full text

Use of an Automated Decision Support Tool Optimizes Clinicians’ Ability to Interpret and Appropriately Respond to Structured Self-Monitoring of Blood Glucose Data

Helena W. Rodbard, Oliver Schnell, Jeffrey Unger et al. · Diabetes Care · 2012 · 28 citations · Full text

Rows per page

1–5 of 10